Clinical Trial Update: Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for PEP02 as second-line therapy in metastatic pancreatic cancer has completed recruitment and status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neoplasms

Drugs mentioned

• PEP02

Snippet

Sponsor: PharmaEngine | Conditions: Pancreatic Neoplasms | Phase 2 | Status: COMPLETED